HSBC Predicts Biogen's Q1 Earnings (NASDAQ:BIIB)

Key Points

• HSBC forecasts Q1 2026 EPS of $2.87 for Biogen and has issued a "Reduce" rating with a $150 price target, a notable divergence from the MarketBeat average target of $208.23.
• Biogen is pursuing pipeline and regional expansion—agreeing to buy Greater China rights to felzartamab for up to $850M and announcing deals (Apellis acquisition, Alloy collaboration)—moves that, along with a Wells Fargo upgrade to Overweight (PT $250), support a stronger growth narrative.
• Context and risk: Biogen beat last quarter's EPS ($1.99 vs. $1.61) despite revenue down 7.2% YoY, trades around $183, holds a consensus "Hold" rating, and faces potential short-term volatility if Q1 or guidance disappoints.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Investment analysts at HSBC issued their Q1 2026 earnings per share estimates for shares of Biogen in a research note issued to investors on Friday, April 17th. HSBC analyst M. Herholdt anticipates that the biotechnology company will earn $2.87 per share for the quarter. HSBC has a "Reduce" rating and a $150.00 price target on the stock. The consensus estimate for Biogen's current full-year earnings is $15.70 per share. HSBC also issued estimates for Biogen's Q2 2026 earnings at $4.38 EPS, Q3 2026 earnings at $4.28 EPS, Q4 2026 earnings at $4.53 EPS and FY2030 earnings at $15.53 EPS.

Other analysts also recently issued reports about the company. HC Wainwright raised their target price on Biogen from $228.00 to $237.00 and gave the company a "buy" rating in a research note on Thursday, April 2nd. The Goldman Sachs Group restated a "buy" rating on shares of Biogen in a research note on Monday, February 9th. Royal Bank Of Canada lowered their target price on Biogen from $233.00 to $213.00 and set an "outperform" rating for the company in a research note on Tuesday, April 7th. Oppenheimer raised their target price on Biogen from $250.00 to $275.00 and gave the company an "outperform" rating in a research note on Wednesday, April 1st. Finally, Mizuho raised their target price on Biogen from $207.00 to $236.00 and gave the company an "outperform" rating in a research note on Tuesday, February 10th. Thirteen research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Biogen has a consensus rating of "Hold" and an average target price of $208.23.

Biogen Stock Up 3.4%

Shares of Biogen stock opened at $183.34 on Tuesday. The business has a 50-day moving average of $185.61 and a 200-day moving average of $174.44. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company has a market capitalization of $26.91 billion, a PE ratio of 20.81, a P/E/G ratio of 2.38 and a beta of 0.16. Biogen has a 1-year low of $115.25 and a 1-year high of $202.41.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company's revenue was down 7.2% on a year-over-year basis. During the same period last year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Biogen

A number of hedge funds and other institutional investors have recently bought and sold shares of BIIB. Norges Bank acquired a new position in Biogen in the fourth quarter valued at approximately $464,408,000. Boston Partners acquired a new position in Biogen in the fourth quarter valued at approximately $302,815,000. Fred Alger Management LLC boosted its stake in Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company's stock valued at $140,576,000 after acquiring an additional 796,735 shares during the period. Employees Provident Fund Board acquired a new position in Biogen in the fourth quarter valued at approximately $123,931,000. Finally, Orion Porfolio Solutions LLC boosted its stake in Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company's stock valued at $64,965,000 after acquiring an additional 509,809 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo upgraded Biogen to Overweight and lifted its price target to $250 from $200, citing renewed confidence in Biogen’s Alzheimer’s and broader pipeline prospects — this is a clear catalyst for buying interest. Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act?
• Positive Sentiment: Biogen agreed to buy exclusive Greater China rights to felzartamab from TJ Biopharma for up to $850M, consolidating worldwide rights to an experimental CD38‑directed antibody being studied in Phase 3 — this reduces regional fragmentation of rights and preserves global commercial upside if trials succeed. Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
• Positive Sentiment: Biogen is expanding its targeted‑therapy and antisense efforts via an announced Apellis acquisition and an Alloy Therapeutics collaboration, diversifying growth drivers beyond legacy franchises and supporting a higher growth narrative. Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance
• Positive Sentiment: Screeners and commentators (e.g., Zacks) included BIIB among non‑tech “wide moat” stocks, reinforcing investor perception of durable competitive strengths and supporting multiple expansion. Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio
• Neutral Sentiment: Market commentary notes Biogen’s rising profile on the Nasdaq after recent moves; this reflects attention but not an immediate earnings or cash‑flow change. Biogen Inc. NASDAQ: BIIB Rating Balance Draws Nasdaq Composite Attention
• Negative Sentiment: An earnings preview cautions that analysts expect a marginal drop in Q1 EPS next week; a weaker-than-expected print or conservative guidance could undercut the recent rally and introduce short‑term volatility. Biogen Earnings Preview: What to Expect

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.